Olmesartan medoxomil

Drug Profile

Olmesartan medoxomil

Alternative Names: Alteis; Benetor; Benevas; Benicar; Cardosal; CS 866; CS 866RN; CS-866DM; Ixia; Mencord; Olmec; Olmes; Olmesartan; Olmetec; Olmighty; Olvance™; Omesar; Openvas; Tensonit; Votum

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Allergan; Daewoong Pharmaceutical; Daiichi Sankyo Company; Menarini; Merck & Co; Pfizer; Sun Pharmaceutical Industries
  • Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 26 Oct 2016 First generic equivalent launched in USA for Hypertension (PO)
  • 01 Jan 2016 Daiichi-Sankyo initiates a clinical trial for Hypertension (In the elderly) in Japan (PO) (UMIN000020471)
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top